Alphaeon receives license to market Evosyal in US, internationally

Alphaeon Corp. has received an executive license to market an advanced botulinum toxin type A neurotoxin in the United States and several international markets, the health care company announced.

The product, developed by Daewoong Pharmaceutical in Seoul, South Korea, will be marketed by Alphaeon under the brand name Evosyal, according to a press release.

Robert E. Grant

The license agreement is part of a transaction in which Strathspey Crown Holdings purchased Evolus of Santa Barbara, Calif., for an undisclosed amount, according to the release.

“We are excited to acquire Evolus and have their team of expert neurotoxin scientists and clinicians join us to lead advances within the lifestyle health care industry,” Robert E. Grant, Strathspey Crown chairman and Alphaeon chief executive officer, said in the release. “Evosyal represents the state of the art in both consistent manufacturability and potency as a 900 kDa neurotoxin molecular complex with high purity, both of which we believe will aid in achieving precise, predictable and long-lasting patient outcomes.”

Launched in July 2013, Alphaeon acquired the US license to Teoxane Laboratories’ next-generation hyaluronic acid-based dermal fillers and cosmeceutical products, which are marketed as Teosyal, in August 2013, the release said. Pending FDA approval and relevant international regulatory authorities, Evosyal and Teosyal will be marketed in the United States and internationally. Teosyal is a leading dermal filler in Europe, according to Alphaeon.